NASDAQ: ACIU - AC Immune SA

Rentabilidade por seis meses: -28.35%
Rendimento de dividendos: 0.00%
Setor: Healthcare

Cronograma de promoção AC Immune SA


Sobre a empresa AC Immune SA

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.

mais detalhes
The company is developing Crenezumab, a humanized, conformation-specific monoclonal antibody, which is in Phase II clinical studies trial for the treatment of Alzheimer's disease (AD). It is also developing ACI-24, an anti-Abeta vaccine candidate that is in Phase II clinical study for AD, as well as completed Phase Ib clinical study for Down syndrome; ACI-35, an anti-Tau vaccine candidate that is in Phase Ib/2a clinical study; and Tau- positron emission tomography (PET) imaging tracer, which is in Phase II clinical study. In addition, the company is researching and developing small molecule Tau aggregation inhibitors for AD and NeuroOrphan indications. Further, it has discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. AC Immune SA has license agreements and collaborations with Genentech, Inc.; Biogen International GmbH; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; Eli Lilly and Company; and WuXi Biologics. The company was incorporated in 2003 and is headquartered in Lausanne, Switzerland.

IPO date 2016-09-23
ISIN CH0329023102
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета chf
Сайт https://www.acimmune.com
Цена ао 3.39
Alteração de preço por dia: +0.9242% (2.705)
Alteração de preço por semana: +1.87% (2.68)
Alteração de preço por mês: -18.75% (3.36)
Alteração de preço em 3 meses: -27.2% (3.75)
Mudança de preço em seis meses: -28.35% (3.81)
Mudança de preço por ano: -45.4% (5)
Mudança de preço em 3 anos: -46.78% (5.13)
Mudança de preço em 5 anos: -67.65% (8.44)
Mudança de preço em 10 anos: 0% (2.73)
Mudança de preço desde o início do ano: -19.94% (3.41)

Subestimação

Nome Significado Nota
P/S 21.21 1
P/BV 1.95 7
P/E 0 0
EV/EBITDA -4.75 0
Total: 4.38

Eficiência

Nome Significado Nota
ROA, % -29.67 0
ROE, % -33.76 0
Total: 0

Dividendos

Nome Significado Nota
Div yield, % 0 0
DSI 0 0
Total: 0

Obrigação

Nome Significado Nota
Debt/EBITDA -0.0694 10
Total: 9.6

Impulso de crescimento

Nome Significado Nota
Rentabilidade Revenue, % -86.67 0
Rentabilidade Ebitda, % -211.46 0
Rentabilidade EPS, % -192.8 0
Total: 0

Instituições Volume Compartilhar, %
BVF Inc. 7428379 8.8
Avidity Partners Management, LP 2969800 3.52
Morgan Stanley 1741677 2.06
Platinum Investment Management Ltd 1322462 1.57
Wells Fargo & Company 1146086 1.36
Renaissance Technologies, LLC 425179 0.5
Deutsche Bank Aktiengesellschaft 253375 0.3
Eversept Partners, LP 124589 0.15
Assenagon Asset Management S.A. 111418 0.13
Handelsbanken Fonder AB 101064 0.12

ETF Compartilhar, % Rentabilidade para o ano, % Dividendos, %
Invesco Nasdaq Biotechnology ETF 0.03512 28.58 0.8565
Principal Healthcare Innovators ETF 0.03418 618.5 0.8416
Future Tech ETF 0.03418 426.34 0.8416
ProShares Ultra Nasdaq Biotechnology 0.0238 51.7 0.85651



Supervisor Cargo Pagamento Ano de nascimento
Dr. Andrea Pfeifer Ph.D. Co-Founder, CEO & Director 1.1M 1957 (68 anos)
Mr. Christopher Roberts CFO & VP of Finance N/A 1990 (35 anos)
Mr. Piergiorgio Donati Chief Technical Operations Officer N/A 1971 (54 ano)
Mr. Jean-Fabien Monin Chief Administrative Officer N/A 1971 (54 ano)
Mr. Howard Donovan Chief HR Officer N/A 1976 (49 anos)
Mr. Alexandre Caratsch General Counsel N/A 1966 (59 anos)
Mr. Julian Snow VP of U.S. Finance & Corporate Development N/A
Ms. Madiha Derouazi Chief Scientific Officer N/A 1973 (52 ano)
Dr. Gary Anthony Waanders Ph.D. Senior VP of Investor Relations & Corporate Communications N/A 1964 (61 ano)
Dr. David T. Hickman Head of AD - SME

Endereço: Switzerland, Lausanne, Building B - abrir no Google Maps, abrir mapas Yandex
Site: https://www.acimmune.com